{
    "clinical_study": {
        "@rank": "74083", 
        "brief_summary": {
            "textblock": "To assess the dose proportionality of azithromycin concentrations and toleration when\n      delivered in tablet formulation to HIV-infected patients.\n\n      The need exists to further assess the antibacterial agent azithromycin at differing doses in\n      an HIV-infected population."
        }, 
        "brief_title": "A Study of Azithromycin in HIV-Infected Patients", 
        "condition": [
            "Bacterial Infections", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Bacterial Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "The need exists to further assess the antibacterial agent azithromycin at differing doses in\n      an HIV-infected population.\n\n      Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment,\n      two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out\n      periods."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  CD4 count <= 500 cells/mm3.\n\n          -  NO active AIDS opportunistic infection.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Other active intercurrent illness.\n\n          -  Any condition possibly affecting drug absorption (e.g., ulcers, gastrectomy,\n             HIV-associated enteropathies.\n\n          -  Signs or symptoms of severe illness that would preclude study participation.\n\n          -  Known allergies to macrolide antibiotics.\n\n        Patients with the following prior condition are excluded:\n\n        Clinically important change in baseline status within 4 weeks prior to study entry.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Investigational drugs including treatment IND drugs within 4 weeks prior to study\n             entry.\n\n        Known drug or alcohol dependence."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002344", 
            "org_study_id": "226C", 
            "secondary_id": "066-060"
        }, 
        "intervention": {
            "intervention_name": "Azithromycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "keyword": [
            "Azithromycin", 
            "Bacterial Infections"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85040"
                }, 
                "name": "Harris Laboratories Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Double-Blind Crossover Study Assessing the Dose Proportionality of Azithromycin Tablets in HIV-Infected Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002344"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "Harris Laboratories Inc": "33.448 -112.074"
    }
}